Dextromethorphan

Generic Name: Dextromethorphan

Brand Names: Auvelity, Benylin DM, Bromfed DM, Broncotron, Cepacol Sore Throat Plus Cough, Cheracol D, Children's Nyquil Cold and Cough, Chloraseptic Sore Throat + Cough, Coricidin Hbp Chest Congestion, Coricidin Hbp Cough and Cold, Creomulsion, DM, Dayquil Cough, Delsym, Delsym Cough Plus Chest Congestion DM, Delsym Cough Plus Soothing Action, Delsym Cough Relief Plus Soothing Action, Despec Reformulated Jun 2008, Diabetic Tussin DM, Dimetapp Long Acting Cough Plus Cold, Diphen, G-zyncof, Mucinex Children's Cough, Mucinex Cough, Mucinex DM, Nuedexta, Nyquil Cough, Pediacare Children's Cough and Congestion, Promethazine DM, Robafen Cough, Robafen DM, Robitussin 12 Hour Cough Relief, Robitussin Cough & Congestion, Robitussin Maximum Strength Cough Plus Chest Congestion DM, Robitussin Nighttime Cough DM, Robitussin Pediatric Cough & Cold LA, Robitussin Pediatric Cough Suppressant, Safetussin DM, Safetussin PM, Scot-tussin DM, Scot-tussin Diabetic CF, Scot-tussin Sugar Free DM, Sudafed PE Children's Cold & Cough, Triaminic Day Time Cold & Cough, Tusnel Diabetic

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₅NO

CAS Number: 125-71-3

Unique Ingredient Identifier: 7355X3ROTS

Background: Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors.

Dextromethorphan was granted FDA approval before 3 December 1957.

Indication: Dextromethorphan is indicated in combination with brompheniramine and pseudoephedrine in the treatment of coughs and upper respiratory symptoms associated with allergies or the common cold. Dextromethorphan is also used in combination with guaifenesin as an over-the-counter product to relieve a cough. Dextromethorphan in combination with quinidine is indicat...

Associated Conditions: Allergic cough, Common Cold, Cough, Cough caused by Common Cold, Coughing caused by Allergies, Coughing caused by Bronchitis, Coughing caused by Flu caused by Influenza, Fever, Flu caused by Influenza, Headache, Irritative cough, Itching of the nose, Itching of the throat, Major Depressive Disorder (MDD), Nasal Congestion, Pseudobulbar Affect (PBA), Rhinorrhoea, Sneezing, Cold or flu syndrome, Upper respiratory symptoms, Watery itchy eyes

Associated Therapies: Airway secretion clearance therapy, Bronchodilation, Oropharyngeal antisepsis

Clinical Trials

A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

Phase 1

Active, not recruiting

Conditions: Drug Drug Interaction (DDI)

Interventions: Drug: BMS-984923
Drug: Midazolam
Drug: Caffeine
Drug: dextromethorphan

First Posted Date: 2024-10-09

Last Posted Date: 2024-11-22

Lead Sponsor: Allyx Therapeutics

Target Recruit Count: 36

Registration Number: NCT06632990

Locations: 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States

A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.

Phase 1

Not yet recruiting

Conditions: Hodgkin Lymphoma
Non Hodgkin Lymphoma

First Posted Date: 2024-04-25

Last Posted Date: 2024-08-28

Lead Sponsor: Murdoch Childrens Research Institute

Target Recruit Count: 10

Registration Number: NCT06383338

Locations: 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects

Phase 1

Not yet recruiting

Conditions: Solid Tumor, Adult

Interventions: Drug: JMKX001899
Drug: Itraconazole
Drug: Rifampin
Drug: Midazolam
Drug: dextromethorphan
Drug: Rosuvastatin
Drug: digoxin

First Posted Date: 2024-04-04

Last Posted Date: 2024-04-04

Lead Sponsor: Jemincare

Target Recruit Count: 72

Registration Number: NCT06348290

DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan

Phase 1

Completed

Conditions: Trypanosomiasis, African

Interventions: Drug: Acoziborole
Drug: Dextromethorphan
Drug: Midazolam

First Posted Date: 2023-07-17

Last Posted Date: 2023-07-17

Lead Sponsor: Drugs for Neglected Diseases

Target Recruit Count: 20

Registration Number: NCT05947604

Locations: 🇲🇾
Clinical Research Center (CRC) Ampang Hospital, Kuala Lumpur, Malaysia

Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia

Phase 4

Recruiting

Conditions: Treatment Resistant Schizophrenia

Interventions: Drug: Placebo
Drug: Dextromethorphan

First Posted Date: 2023-07-13

Last Posted Date: 2024-12-19

Lead Sponsor: All India Institute of Medical Sciences, Bhubaneswar

Target Recruit Count: 72

Registration Number: NCT05944510

Locations: 🇮🇳
All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India

A Study of IBI351 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Itraconazole
Drug: IBI351
Drug: Dextromethorphan

First Posted Date: 2023-01-26

Last Posted Date: 2023-10-24

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 24

Registration Number: NCT05699993

Locations: 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China

A Drug Interaction Study of LY3871801 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3871801
Drug: Methotrexate
Drug: Warfarin
Drug: Dextromethorphan
Drug: Midazolam
Drug: Repaglinide

First Posted Date: 2022-11-02

Last Posted Date: 2023-04-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 39

Registration Number: NCT05602675

Locations: 🇺🇸
Covance Dallas, Dallas, Texas, United States

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Imlunestrant
Drug: Omeprazole
Drug: Repaglinide
Drug: Quinidine
Drug: Rosuvastatin
Drug: Dextromethorphan
Drug: Digoxin

First Posted Date: 2022-07-06

Last Posted Date: 2022-11-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 113

Registration Number: NCT05444556

Locations: 🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States